• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1278118 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
3 u  o# ~6 q# lNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 # o/ i" d% t& W! P) P& A+ b9 h
+ Author Affiliations: i4 v& J7 F4 p9 U' `% }
: A: `" O8 F3 K& S- K
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan " K; {- ?7 r; c$ [
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ( i. F5 I% T1 i' O( k* C- ?& S% R  f
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: N* t0 r7 R% ~  L) w4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 4 J1 Y! J" C- Y) P- L
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan * p/ E. Q& L1 P3 {
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
! k4 `* B! h9 A0 U4 ?% [' t7Kinki University School of Medicine, Osaka 589-8511, Japan ( n1 \3 D- j" T$ h6 z) n% ]# F
8Izumi Municipal Hospital, Osaka 594-0071, Japan ) G# i' ~; q' i$ a
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ' G( Q7 r5 l7 s+ ]
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
& I* }) _3 r. ~$ I; \+ S) sAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
3 T7 y: f9 A/ o" Z- U. T& n3 r  C6 d
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type   B( @7 ^6 m( t
" m' w% h: ]$ V2 Y6 |- J) [
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
. D) D8 Q' t* w4 Y, X/ O  d" v' g  {" j3 X
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
4 \  T! Y7 P3 L) f% Q
7 |  l- G0 k4 e; xPublished online on: Thursday, December 1, 2011 - f" C+ J; f4 `) V5 k, ~$ ^, M6 m

3 H4 y+ w( x6 D( JDoi: 10.3892/ol.2011.507 1 V# F# H) P( d  [0 V% M' @7 @
7 I% Y0 P4 ~2 |) F. [5 m8 J
Pages: 405-410
8 x. j% s2 K. k% t% F7 W& i5 x$ b; v; \& a) u# n
Abstract:7 B) E0 \6 q6 u& s
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
; k# Z' Z# d; R 8 L! U# ^* e) `9 y  K
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population1 a* O- M: K% s. b
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
5 w8 t* s- I- ], H. x8 u9 p' d6 `+ Author Affiliations9 u! d/ J0 u0 T5 _# a
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 8 [) Q6 N: b, I5 g0 o
2Department of Thoracic Surgery, Kyoto University, Kyoto
2 Y$ L4 T7 v' A" S2 j: n  U3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
: J+ G5 m6 J" b0 R8 R8 i&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
* c; d( N: D& c3 XReceived September 3, 2010. $ n2 [( `% P6 o2 y6 h  v) Q
Revision received November 11, 2010.
/ c* N; j' Z1 R4 p+ _& ^Accepted November 17, 2010. . U# O5 b/ b( w0 F- ^& x8 J4 G7 R1 ?% [
Abstract  T$ g" y# \) E" L. G% P. _* t9 Z8 {
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
$ Y; \% s  {3 SPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. + I" w9 e1 {; U' ]: Q
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. " c0 `' r! ?# k/ J7 ?  [4 u
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.   F9 \' n" T  x: q- @
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。: a3 }8 H- S% e8 I
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
/ W* \! G6 @# C* ~0 P
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy- a, x1 |: m8 Z- r
http://clinicaltrials.gov/ct2/show/NCT01523587) y6 N% Q3 O4 x) I8 [1 `

# I8 a3 [/ ]6 g$ @  L0 K& a( G. Z9 qBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC+ b3 T4 V2 }7 z/ e9 u; i! i
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 . d' o- i( |% x5 S' z" G

# p7 |: v1 }$ f: @* M从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
6 n8 u  v: v( t# ^/ E$ e* A" k8 A至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 - T: x1 ?0 e+ R4 |) T2 ^' q5 `
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
. z. F4 g4 M; O, A4 P% ?至今为止,未出 ...

6 ~. k$ F3 ^- Z5 D没有副作用是第一追求,效果显著是第二追求。
6 G0 k/ T2 \. N3 [# R( ^9 k不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表